The R1507 antibody was created by Genmab under the company’s agreement with Roche and initiation of the trial will trigger a milestone payment to Genmab of $500,000.
Lisa Drakeman, CEO of Genmab, said: “R1507 will be the first antibody created by Genmab under our agreement with Roche to enter Phase II development. We believe that R1507 may offer an additional treatment option to sarcoma patients.”